Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease
- PMID: 17226906
- PMCID: PMC4065955
- DOI: 10.3748/wjg.v13.i2.264
Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease
Abstract
Aim: To comparatively evaluate the long term efficacy of Rifaximin and dietary fibers in reducing symptoms and/or complication frequency in symptomatic, uncomplicated diverticular disease.
Methods: 307 patients (118 males, 189 females, age range: 40-80 years) were enrolled in the study and randomly assigned to: Rifaximin (400 mg bid for 7 d every month) plus dietary fiber supplementation (at least 20 gr/d) or dietary fiber supplementation alone. The study duration was 24 mo; both clinical examination and symptoms' questionnaire were performed every two months.
Results: Both treatments reduced symptom frequency, but Rifaximin at a greater extent, when compared to basal values. Symptomatic score declined during both treatments, but a greater reduction was evident in the Rifaximin group (6.4 +/- 2.8 and 6.2 +/- 2.6 at enrollment, P = NS, 1.0 +/- 0.7 and 2.4 +/- 1.7 after 24 mo, P < 0.001, respectively). Probability of symptom reduction was higher and complication frequency lower (Kaplan-Meyer method) in the Rifaximin group (P < 0.0001 and 0.028, respectively).
Conclusion: In patients with symptomatic, uncomplicated diverticular disease, cyclic administration of Rifaximin plus dietary fiber supplementation is more effective in reducing both symptom and complication frequency than simple dietary fiber supplementation. Long term administration of the poorly absorbed antibiotic Rifaximin is safe and well tolerated by the patients, confirming the usefulness of this therapeutic strategy in the overall management of diverticular disease.
Figures



Similar articles
-
Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial.Aliment Pharmacol Ther. 1995 Feb;9(1):33-9. doi: 10.1111/j.1365-2036.1995.tb00348.x. Aliment Pharmacol Ther. 1995. PMID: 7766741 Clinical Trial.
-
Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease.Aliment Pharmacol Ther. 2011 Apr;33(8):902-10. doi: 10.1111/j.1365-2036.2011.04606.x. Epub 2011 Mar 2. Aliment Pharmacol Ther. 2011. PMID: 21366632
-
Rifaximin in the management of colonic diverticular disease.Expert Rev Gastroenterol Hepatol. 2009 Dec;3(6):585-98. doi: 10.1586/egh.09.63. Expert Rev Gastroenterol Hepatol. 2009. PMID: 19929580
-
[Role of rifaximin in the treatment of colonic diverticular disease].Clin Ter. 2012;163(1):33-8. Clin Ter. 2012. PMID: 22362232 Review. Italian.
-
Cyclic antibiotic therapy for diverticular disease: a critical reappraisal.J Gastrointestin Liver Dis. 2010 Sep;19(3):295-302. J Gastrointestin Liver Dis. 2010. PMID: 20922195 Review.
Cited by
-
Non-interventional study evaluating efficacy and tolerability of rifaximin for treatment of uncomplicated diverticular disease.Wien Klin Wochenschr. 2014 Jan;126(1-2):9-14. doi: 10.1007/s00508-013-0447-7. Epub 2013 Nov 16. Wien Klin Wochenschr. 2014. PMID: 24240607 Clinical Trial.
-
Preventing recurrent acute diverticulitis with pharmacological therapies.Ther Adv Chronic Dis. 2013 Nov;4(6):277-86. doi: 10.1177/2040622313498809. Ther Adv Chronic Dis. 2013. PMID: 24179670 Free PMC article.
-
Management of colonic diverticular disease with poorly absorbed antibiotics and other therapies.Therap Adv Gastroenterol. 2011 Nov;4(6):365-74. doi: 10.1177/1756283X11412820. Therap Adv Gastroenterol. 2011. PMID: 22043229 Free PMC article.
-
Development and validation of a diverticular clinical score for symptomatic uncomplicated diverticular disease after acute diverticulitis in a prospective patient cohort.Therap Adv Gastroenterol. 2020 May 8;13:1756284820913210. doi: 10.1177/1756284820913210. eCollection 2020. Therap Adv Gastroenterol. 2020. PMID: 32523619 Free PMC article.
-
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.World J Gastroenterol. 2015 Nov 21;21(43):12322-33. doi: 10.3748/wjg.v21.i43.12322. World J Gastroenterol. 2015. PMID: 26604640 Free PMC article. Review.
References
-
- Stollman N, Raskin JB. Diverticular disease of the colon. Lancet. 2004;363:631–639. - PubMed
-
- Delvaux M. Diverticular disease of the colon in Europe: epidemiology, impact on citizen health and prevention. Aliment Pharmacol Ther. 2003;18 Suppl 3:71–74. - PubMed
-
- Parks TG. Natural history of diverticular disease of the colon. Clin Gastroenterol. 1975;4:53–69. - PubMed
-
- Kang JY, Melville D, Maxwell JD. Epidemiology and management of diverticular disease of the colon. Drugs Aging. 2004;21:211–228. - PubMed
-
- Farmakis N, Tudor RG, Keighley MR. The 5-year natural history of complicated diverticular disease. Br J Surg. 1994;81:733–735. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous